Original Article
Comparative immunoprofiling of polymyositis and dermatomyositis muscles

Kun Huang1,2, Qiu-Xiang Li1, Fang-Fang Bi1, Hui-Qian Duan1, Frank Mastaglia3,4, Yue-Bei Luo1,*, Huan Yang1,*

1Department of Neurology, Xiangya Hospital, Central South University, Changsha, China; 2Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan; 3Perron Institute for Neurological and Translational Science, Nedlands, Australia; 4Institute for Immunology & Infectious Diseases, Murdoch University, Perth, Australia. *Equal contributors.

Received April 14, 2018; Accepted July 18, 2018; Epub August 1, 2018; Published August 15, 2018

Abstract: The morphological, immunohistochemical, and immunopathological analyses of muscle biopsy are essential for the diagnosis of idiopathic inflammatory myopathies (IIMs). However, they are also one of the most common causes of misdiagnosis. Although several diagnostic criteria have been proposed for the diagnosis of IIMs, misdiagnosis still remains common in clinical practice. The present study aims to characterize the inflammatory profile of IIMs, including the expression of MHC-I, MHC-II, MAC and infiltrating cells. We also investigated the sensitivity and specificity of MHC-I and MHC-II immunostaining for the diagnosis of IIMs. We found that the expression of MHC-I and MHC-II was both higher in IIMs than in non-inflammatory myopathies (NIMs). The distribution of MHC-I in IIMs is different from that of MHC-II. MHC-I is mainly located in the sarcoplams, while MHC-II is located mostly on the sarcolemmas. Moreover, our findings suggest that MAC may be a potential marker to diagnose DM, and the combination of MHC-I and MHC-II immunostaining results in a higher sensitivity and specificity for IIM diagnosis, especially for DM. In addition, infiltrating cells in PM were mainly CD8+ cells, but we found in DM and NIMs they were primarily CD4+ cells, which is consistent with previous studies. Lastly, glucocorticoid treatment and disease duration have little effect on the MHC-I and MHC-II expression pattern. Our findings indicate that the immunostaining of inflammatory markers such as MHC-I, MHC-II, CD4, CD8, CD303 and MAC are of diagnostic value for IIMs regardless of the immunosuppression regime and disease duration.

Keywords: Polymyositis, dermatomyositis, major histocompatibility complex, inflammatory cells, membrane attack complex

Introduction

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders comprised of dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), and necrotizing autoimmune myopathy [1-3]. The most remarkable myopathological feature of IIMs is the infiltration of inflammatory cells surrounding muscle fascicles or invading muscle fibers [4]. However, inflammatory infiltrates are not specific to IIMs and can be present in other genetic and acquired myopathies such as muscular dystrophy and myasthenia gravis, which, if omitting the clinical pictures, may lead to the misdiagnosis of IIMs [5-7].

The 1975 Bohan and Peter criteria are still some of the most widely-used criteria in clinical practice [1, 2]. However, the criteria proposed in earlier times do not emphasize immunological characterization as part of the muscle pathology investigation, except for the Dalakas criteria [5], the first criteria introducing the profiling of inflammatory cells, in which CD8+ cells invading major histocompatibility complex (MHC) class I upregulated muscle fibers are used to define PM and thus significantly improve diagnostic specificity. The ENMC criteria [8] also use CD8+ cells invading non-necrotic fibers or ubiquitous MHC-I expression for PM diagnosis, and MAC deposition or perifascicular MHC-I expression for DM. However, one recent study shows that the CD8-MHC-I complex can also be present in PM, IBM and other unclassifiable myositis patients, which challenges the specificity of the CD8-MHC-I complex for PM [9]. Meanwhile, the distribution of MHC-I and
MHC-II molecules has seldom been evaluated in previous studies.

Immunological profiling of muscle biopsy holds significant diagnostic value and provides clues to pathogenesis. Firstly, both MHC-I and MHC-II are cell surface molecules whose major biological function is to present exogenous and endogenous antigens to immune cells. They are histochemically undetectable in normal human muscle fibers but upregulated in IIMs [10, 11]. Despite the generally accepted diagnostic value of ubiquitous or perifascicular expressions of MHC-I and MHC-II in PM and DM, they were also found to be upregulated in other primary muscle disorders like muscular dystrophy, which compromises the specificity of MHC-I immunostaining for IIM diagnosis [12]. Secondly, the deposition of membrane attack complex (MAC) can be found in the blood vessels, muscle fibers, and skin lesions of DM. MAC is believed to be involved in perimysial and perifascicular damage, which is the characteristic histological change of perifascicular atrophy [13, 14]. Lastly, in DM, where the humoral mediated process is considered as the main pathogenic event, the inflammatory cells are predominantly CD4+ cells and B lymphocytes, while in PM, CD8+ cells invading MHC-I upregulated muscle indicates cellular immunity is the core etiology [15, 16].

Although the expressions of MHC-I and MHC-II are emphasized in the diagnosis of IIMs, in our opinion, the diagnostic value of MHC-I and MHC-II may be underestimated. In the present study, we aim to determine the expression patterns of MHC-I, MHC-II, MAC and inflammatory cells in PM, DM and non-inflammatory myopathy (NIM) patients from our neuromuscular center. Particular attention was also paid to the utility of distribution of MHC-I and MHC-II in differentiating IIMs from NIMs. We also investigated the effect of disease duration and glucocorticoid on immunohistochemical staining in PM and DM.

Materials and methods

Patients

With the approval of the Ethics Committee of Xiangya Hospital, Central South University, a total of 89 Chinese patients, including 71 cases of IIMs and 18 cases of NIMs, in the neuromuscular center of Xiangya Hospital of Central South University from 2012 to 2016 were included. The diagnosis of IIM was made according to the Bohan and Peter criteria [1, 2]. The IIM patients included 44 cases of PM and 27 cases of DM, but no IBM cases were included as the low number of patients might skew the statistical analysis. NIMs consisted of 12 cases of dystrophinopathy and 6 of dysferlinopathy with secondary muscle inflammation, diagnosed based on pathological findings of muscle biopsy and/or genetic testing. In addition, 6 cases that exhibited no muscle pathology changes and were devoid of any neuromuscular diseases were recruited as the normal control group. All patients provided written consent forms.

Muscle biopsies

Open muscle biopsies were taken from biceps brachii or gastrocnemius. The muscle samples were immediately frozen in isopentane cooled with liquid nitrogen and stored at -80°C. Subsequent routine histological and immunohistochemical analysis was performed on the 8 µm cryostat sections.

Routine histological staining

Routine histological staining techniques included hematoxylin and eosin (H&E), modified Gomöri trichrome, acid phosphatase, periodic acid-Schiff (PAS), Oil red O, NADH-TR, ATPase (pH = 4.3, 4.6, 11.0), succinic dehydrogenase (SDH), and cytochrome C oxidase (COX).

Immunohistochemical staining

Sections were fixed for 10 minutes in acetone at -20°C, incubated in 0.3% H2O2 solution (Sigma) in phosphate-buffered saline (PBS 0.01 M, pH 7.4, Sigma) for 10 minutes and subsequently blocked in 10% fetal bovine serum.

Table 1. Antibodies employed in the present study

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Species</th>
<th>Dilution</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC-I</td>
<td>Mouse anti-human monoclonal 1:100</td>
<td>BioLegend</td>
<td></td>
</tr>
<tr>
<td>MHC-II</td>
<td>Rabbit anti-human monoclonal 1:100</td>
<td>Abcam</td>
<td></td>
</tr>
<tr>
<td>CD4</td>
<td>Mouse anti-human monoclonal 1:100</td>
<td>BD Biosciences</td>
<td></td>
</tr>
<tr>
<td>CD8</td>
<td>Mouse anti-human monoclonal 1:200</td>
<td>BD Biosciences</td>
<td></td>
</tr>
<tr>
<td>CD303</td>
<td>Mouse anti-human monoclonal 1:100</td>
<td>BD Biosciences</td>
<td></td>
</tr>
<tr>
<td>MAC</td>
<td>Mouse anti-human monoclonal 1:100</td>
<td>Abcam</td>
<td></td>
</tr>
</tbody>
</table>
Immunoprofiling of polymyositis and dermatomyositis

Table 2. Clinical characteristics of each subgroup

<table>
<thead>
<tr>
<th>Group</th>
<th>Subgroup</th>
<th>No.</th>
<th>Male:Female</th>
<th>Age (year, Mean ± SEM)</th>
<th>Disease duration (month, Mean ± SEM)</th>
<th>CK (U/L, Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIMs</td>
<td>PM</td>
<td>44</td>
<td>9:13</td>
<td>44.6±2.2</td>
<td>15.2±3.7</td>
<td>2307.7±381.2</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>27</td>
<td>1:2</td>
<td>36.5±3.9</td>
<td>8.5±2.1</td>
<td>4222.8±734.1</td>
</tr>
<tr>
<td>NIMs</td>
<td>Dystrophinopathy</td>
<td>12</td>
<td>5:1</td>
<td>16.4±3.9</td>
<td>98.0±20.4</td>
<td>5205.8±912.6</td>
</tr>
<tr>
<td></td>
<td>Dysferlinopathy</td>
<td>6</td>
<td>5:1</td>
<td>35.0±2.0</td>
<td>90.0±36.1</td>
<td>5528.8±901.5</td>
</tr>
</tbody>
</table>

Table 3. Average proportions of positive staining for MHC-I in each group

<table>
<thead>
<tr>
<th>Group</th>
<th>Position</th>
<th>Sarcoplasmic (%)</th>
<th>Sarcolemmal (%)</th>
<th>Complete sarcolemmal (%)</th>
<th>Partial sarcolemmal (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIMs</td>
<td>Sarcoplasmic</td>
<td>71.8</td>
<td>61.9</td>
<td>35.6</td>
<td>26.3</td>
</tr>
<tr>
<td></td>
<td>Sarcolemmal</td>
<td>5.7</td>
<td>21.4</td>
<td>6.1</td>
<td>15.3</td>
</tr>
<tr>
<td>NIMs</td>
<td>Sarcoplasmic</td>
<td>22.2</td>
<td>32.2</td>
<td>8.0</td>
<td>24.2</td>
</tr>
<tr>
<td></td>
<td>Sarcolemmal</td>
<td>62.0</td>
<td>50.2</td>
<td>24.9</td>
<td>25.3</td>
</tr>
<tr>
<td>PM</td>
<td>Sarcoplasmic</td>
<td>87.9</td>
<td>81.1</td>
<td>53.1</td>
<td>28.0</td>
</tr>
<tr>
<td>DM</td>
<td>Sarcoplasmic</td>
<td>22.8</td>
<td>35.3</td>
<td>9.8</td>
<td>25.4</td>
</tr>
<tr>
<td>Dystrophinopathy</td>
<td>Sarcoplasmic</td>
<td>21.0</td>
<td>26.2</td>
<td>4.3</td>
<td>21.8</td>
</tr>
</tbody>
</table>

Table 4. Average proportions of positive staining for MHC-II in each group

<table>
<thead>
<tr>
<th>Group</th>
<th>Pattern</th>
<th>Sarcoplasmic (%)</th>
<th>Sarcolemmal (%)</th>
<th>Complete sarcolemmal (%)</th>
<th>Partial sarcolemmal (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIMs</td>
<td>Sarcoplasmic</td>
<td>5.7</td>
<td>21.4</td>
<td>6.1</td>
<td>15.3</td>
</tr>
<tr>
<td></td>
<td>Sarcolemmal</td>
<td>1.6</td>
<td>4.8</td>
<td>2.3</td>
<td>2.5</td>
</tr>
<tr>
<td>NIMs</td>
<td>Sarcoplasmic</td>
<td>6.5</td>
<td>19.5</td>
<td>5.4</td>
<td>14.1</td>
</tr>
<tr>
<td></td>
<td>Sarcolemmal</td>
<td>4.5</td>
<td>24.4</td>
<td>7.3</td>
<td>17.2</td>
</tr>
<tr>
<td>PM</td>
<td>Sarcoplasmic</td>
<td>0.7</td>
<td>1.8</td>
<td>0.5</td>
<td>1.3</td>
</tr>
<tr>
<td>DM</td>
<td>Sarcoplasmic</td>
<td>3.5</td>
<td>10.8</td>
<td>5.8</td>
<td>5.0</td>
</tr>
</tbody>
</table>

(Sigma) for 45 minutes. After the PBS wash, the samples were incubated with a primary antibody (Table 1) at 37°C for 3 hours. Then, they were rinsed in PBS and treated with a secondary antibody for 30 min at 37°C. An ABC kit was used (VECTASTAIN Elite ABC Kit PK-6100) according to the manufacturer’s recommendations, and the samples were treated with DAB (Sigma) for several minutes. Finally, the sections were sealed in neutral balsam.

Light microscopy

All muscle samples were evaluated blindly by two experienced myopathologists. The patterns of MHC-I and MHC-II staining were categorized as sarcolemmal and sarcoplasmic. Moreover, sarcolemmal staining was classified as being completed sarcolemmal or partial sarcolemmal, depending on whether it involved the entire surface of the myofibers or was patchy in its distribution. The expression of MHC-I and MHC-II was assessed under at least six random different views of 200 magnification. The ratio of positively stained fibers to total non-necrotic myofibers was calculated.

The quantification of CD4+ and CD8+ cells was assessed in at least six random microscopic fields at 200 magnification. The ratios of immunoreactive inflammatory cells to total inflammatory cells in all the fields were calculated. The quantification of CD303+ plasmacytoid dendritic cells (pDCs) was performed with the hot spot method [17, 18] and used for myositis because of the relatively low frequency of inflammatory cell infiltration. This method allows the quantification of cells in hot spots, defined as muscle areas containing the highest density of positive cells. Accordingly, six hot spots per muscle section were selected for CD303+ pDC quantification.

The patterns of MAC were classified as endomysial, perimysial, capillary perivascular, or endomysial arteriolar and were assessed by
observing the whole section. The ratio of positively stained cases to the total cases was calculated in each specific region.

Data analysis

The Pearson chi-square ($\chi^2$) test was used to compare the frequency distribution of categorical variables. Student's t-test or one-way ANOVA followed by Bonferroni's post-hoc test were used to compare the mean values among various groups of cases and controls. The statistical analysis was performed using Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) Version 20. A p-value <0.05 was considered statistically significant.

Results

Demographic and clinical features

There was a female predominance in IIM patients (male: female = 27:44), compared with the male predominance in NIM (male:female = 5:1, $P = 0.001$), which was partly due to the male dystrophinopathy patients. The CK levels of NIM patients were generally higher than those of IIMs ($P = 0.023$), while they were even higher in DM than in PM. Further details of the demographic statistics of the subgroups are listed in Table 2.

Patterns of MHC-I and MHC-II staining

All IIM and NIM cases showed MHC-I positive staining except for one PM patient, while on MHC-II staining, 70.4% of the IIMs and 22.2% of the NIMs showed positivity ($P = 0.001$). The average proportions of positive staining for MHC-I and MHC-II in IIMs, NIMs and each subgroup are shown in Tables 3, 4. There was no MHC-I or MHC-II immunoreactivity in any of the normal control samples (Figure 1), and no case with MHC-II immunopositivity in the absence of MHC-I staining.

In terms of sarcolemmal staining, the pattern of MHC-I in the IIMs was more complete than partial ($P = 0.012$), but it was more partial than complete in the NIMs ($P = 0.000$). MHC-I immunoreactivity in the IIMs was mainly in the sarcoplasm instead of on the sarcolemmas ($P = 0.001$). More specifically, MHC-I staining was more sarcoplasmic than sarcolemmal in PM ($P = 0.001$), while in DM, the staining of sarcolemmal MHC-I was more complete than partial ($P = 0.000$).
Immunoprofiling of polymyositis and dermatomyositis

The MHC-II immunoreactivity in the IIMs was mostly sarcolemmal rather than sarcoplasmic \((P = 0.000)\), and more partial than complete \((P = 0.000)\). In the NIMs, there was no difference between the MHC-II sarcolemmal and sarcoplasmic staining.

**Diagnostic value of MHC-I and MHC-II**

We used 35% and 20% as the cut-off points for the MHC-I sarcoplasmic and MHC-II partial sarcolemmal staining positivity respectively, which resulted in a sensitivity of 0.859 and a specificity of 0.833 for IIMs. To compare the DM with the NIMs, if MHC-I complete sarcolemmal staining was observed in more than 25% of the muscle fibers or MHC-II partial sarcolemmal staining in more than 22.5% of the muscle fibers, the sensitivity would be 0.963 and the specificity be 1.000 for DM. In the case of MHC-I sarcoplasmic staining being positive in more than 35% of the muscle fibers or MHC-II complete sarcolemmal staining in more than 15.5% of the muscle fibers, the sensitivity and specificity of diagnosis of PM was 0.841 and 0.833 respectively.

Given that one single index was used for IIMs diagnosis, MHC-I showed a better diagnostic value than MHC-II. For example, for the differentiation of the DM from the NIMs, MHC-I had a sensitivity and a specificity as 0.926 and 1.000 respectively, while MHC-II had only 0.778 and 0.778 respectively. However, by combining MHC-I and MHC-II, the sensitivity and specificity for DM diagnosis was improved to 0.963 and 1.000 respectively.

**Profile of the infiltrating inflammatory cells**

In PM, inflammatory cells were mainly located in clusters in the endomysium as well as the perimysium, whereas in DM, they were mainly perivascular and perifascicular. In NIMs, scattered inflammatory cells were observed mainly in the endomysium and perimysium (**Figure 2**). The frequencies of inflammatory cells in all
groups are listed in Table 5. No inflammatory cells were found in the normal control group.

CD4+, CD8+ and CD303+ cells were more frequent in IIMs than in NIMs (Figure 3). Moreover, CD8+ and CD303+ cells were more frequent in PM than DM ($P<0.001$, 0.01). In accordance with previous studies, the majority of the inflammatory cells in PM were CD8+ cells ($P=0.043$), but CD4+ cells were the majority in DM and NIMs ($P=0.000$, 0.000).

**Immunohistostaining pattern of MAC**

DM patients demonstrated more frequent capillary perivascular MAC than PM patients ($P=0.000$). No NIMs showed MAC positivity on perivascular spaces. The frequencies of MAC positive staining in all groups are listed in Table 6. No other significant difference was observed in the endomysial, perimysial, or endomysial arteriolar MAC staining patterns. On the basis of perivascular MAC staining in DM and other myopathies including PM and NIMs, MAC showed a sensitivity of 0.889 and specificity of 0.903 to differentiate DM from other myopathies. The normal control cases showed no MAC immunoreactivity (Figure 4).

**Effects of disease duration and glucocorticoid on inflammatory profiles of PM and DM**

Based on the disease duration upon the muscle biopsy date, PM and DM patients were categorized into two groups respectively: the S group (duration shorter than three months) and the L group (duration longer than three months). PM-L consisted of 28 cases and PM-S 16, while DM-L included 19 cases and DM-S 8. The frequencies of CD4+ and CD303+ cells were higher in DM-L than in DM-S ($P=0.003$, 0.011). No other significant difference was identified in MHC-I, MHC-II and CD8+ T cells between PM-L and PM-S, or between DM-L and DM-S.

PM and DM patients were also divided into two groups depending on the usage of glucocorticoid: GC (glucocorticoid used in the 4 weeks before biopsy) and NGC group (no glucocorticoid used in the 4 weeks before biopsy).
Table 6. Positive rates of MAC at different location in each group

<table>
<thead>
<tr>
<th>Group</th>
<th>Endomysium (%)</th>
<th>Perimysium (%)</th>
<th>Capillary perivascular (%)</th>
<th>Endomysial arteriole (%)</th>
<th>Total positivity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>54.5</td>
<td>15.9</td>
<td>13.6</td>
<td>36.4</td>
<td>93.2</td>
</tr>
<tr>
<td>DM</td>
<td>33.3</td>
<td>29.6</td>
<td>88.9</td>
<td>37.0</td>
<td>92.6</td>
</tr>
<tr>
<td>Dystrophinopathy</td>
<td>8.3</td>
<td>8.3</td>
<td>0.0</td>
<td>8.3</td>
<td>41.7</td>
</tr>
<tr>
<td>Dysferlinopathy</td>
<td>83.3</td>
<td>0.0</td>
<td>0.0</td>
<td>66.7</td>
<td>83.3</td>
</tr>
</tbody>
</table>

PM-NGC consisted of 37 cases and PM-GC 7 cases, DM-NGC 19 cases and DM-GC 8 cases. There was no significant difference in MHC-I, MHC-II and inflammatory cell subtypes between PM-GC and PM-NGC, or between DM-GC and DM-NGC group.

Profile of MHC-I, MHC-II and infiltrating inflammatory cells between isolated IIMs and overlap IIMs

The IIM patients were classified into two groups based on whether or not they were associated with connective tissue diseases (CTDs) at the time of muscle biopsy: isolated IIMs and overlap IIMs. The overlap IIMs composed of five cases, including three DM patients associated with rheumatoid arthritis, one DM patient with systemic sclerosis, and one PM patient with systemic lupus erythematosus. The overlap IIMs accounted for 7.0% of all the IIMs, in which the overlap DMs were 14.8% of the DMs and the overlap PMs were 2.3% of the PMs in our study. No significant difference was detected in MHC-I, MHC-II and inflammatory cell subtypes either between isolated IIMs and overlap IIMs, or between isolated DM and overlap DM group.

Discussion

In the present study, the patterns of sarcolemmal and sarcoplasmic staining of MHC-I and MHC-II in non-necrotic myofibers were evaluated qualitatively. The sarcolemmal staining pattern was further categorized as complete or partial. The salient point of our study is that by quantifying MHC-I and MHC-II staining in the sarcolemmas and sarcoplasm, we find that MHC-I and MHC-II are good diagnostic markers in combination to diagnose IIMs with a sensitivity and specificity both higher than 0.833. For DM diagnosis, the sensitivity and specificity are both higher than 0.963, which is relatively high compared with previous studies [11, 12]. The distribution of MHC-I and MHC-II immunoreactivity in IIMs and NIMs was also different in our research. In IIMs, MHC-I is mostly expressed in sarcoplasmic, while MHC-II is basically expressed in sarcolemmas. No significant difference was identified on the MHC-I and MHC-II distribution of sarcoplasm and sarcolemmas in NIMs. Our study is the first to report and quantify the distribution of MHC-I and MHC-II in IIMs muscles for IIM diagnosis.

The percentages of CD4+, CD8+ and CD303+ cells in IIMs are higher than those in NIMs in our research, which suggests that the inflammation in dystrophinopathy and dysferlinopa-
Immunoprofiling of polymyositis and dermatomyositis

It is more likely a secondary immune response to muscle damage. It has long been established that interstitial and perivascular inflammation in PM are predominantly CD8+ cells, and in DM CD4+ cells [15, 16]. In comparison, CD4+ cell-predominant focal inflammatory infiltrates can sometimes be found on muscle biopsies of dysferlinopathy [19, 20]. In our study, CD8+ cells are the major inflammatory cells in PM, and CD4+ cells are most abundant in DM and NIMs. These findings again support the conclusion that cytotoxicity mediates muscle fiber injuries in PM and the humoral immunity in DM.

Dendritic cells (DCs) are professional antigen-presenting cells supporting adaptive and innate immune responses [21]. They can be divided into two types: myeloid DCs (mDCs) involved in specific adaptive immune response and plasmacytoid DCs (pDCs) which have a key role in innate immunity. pDCs are found mainly in DM while mDCs predominate in PM and IBM [22, 23]. In the present study, CD303+ pDCs are more frequent in PM than DM, which is contrary to previous findings. This may be due to the following reasons. Firstly, the hot spot method of CD303+ pDCs calculation in our study was different from the quantification method used in previous studies. Secondly, CD303+ pDCs in DM showed a more scattered distribution in the perimysium than in PM in our study, combined with the hot spot method for CD303+ pDCs quantification, hence in our study the percentage of CD303+ pDCs in PM is higher than DM. Lastly, the immune response in Chinese IIMs may be different from that in other populations.

DM is considered a microangiopathy caused by MAC mediated complement cascade activation [24-27]. In our study, MAC positivity can be observed in the endomysium, perimysium, on the walls of intramuscular endomysial capillaries and arterioles in IIMs as well as NIMs. Taking distribution patterns into consideration, capillary and perivascular deposition of MAC in DM is much higher than in PM and NIMs. MAC deposition in the capillary walls of endomysial microvessels is deemed highly specific to DM, especially in childhood DM [13, 24]. However, one recent study by Braczynski [28] reports that the capillary MAC deposits’ diagnostic value may be overestimated for DM. In our study, although the microvessel MAC immunopositivity is also detected in other myositis, endomysial capillary MAC immunopositivity for the diagnosis of DM gives a relatively high sensitivity of 0.889 and specificity of 0.903. Thus, we confirm that capillary perivascular deposition of MAC can be used as an important part of the diagnostic workup for DM.

It has been shown that immunosuppressive treatment in IIMs has little effect on MHC-I expression, hence making MHC-I a useful diagnostic marker for IIMs regardless of previous treatment [29]. Recent studies have also discovered that corticosteroid therapy has little influence on the presence or degree of inflammatory infiltrates in IIMs [30]. Our study shows that glucocorticoid treatment within 4 weeks before biopsy does not affect the immunoreactivity of MHC-I and MHC-II, nor does it change the subtype of inflammatory cells. Moreover, we have shown that the disease duration also has little effect on the expression of MHC-I and MHC-II, which has not been reported before. This phenomenon suggests that the overexpression of MHC-I and MHC-II is sustained throughout the whole disease duration and plays an essential role in disease pathogenesis. Besides, the CD303+ pDCs in our study, at the late stage of DM, were higher than in the early stage, which refutes an initiation role of pDCs in DM etiology.

In our study, IIMs are categorized into two groups: isolated and overlap. We find that there is no difference in the immunoreactivity of MHC-I, MHC-II and the subtype of inflammatory cells between the isolated and overlap groups in IIMs, which has been only rarely reported before. The underlying mechanism remains elusive, but we consider these phenomena strongly indicate a common immunologic pathogenesis between overlap and isolated IIMs [31].

In conclusion, our study shows that by the quantitative analysis of sarcolemmal and sarcoplasmic staining, MHC-I and MHC-II are sensitive and specific markers for IIM diagnosis, and especially for DM diagnosis. In addition, our findings indicate that regardless of the disease duration, the immunosuppression regime, or CTD overlapping, the immunohistochemical staining for inflammatory markers, such as MHC-I, MHC-II, CD4, CD8, CD303 and MAC, are of diagnostic value for IIMs.

Acknowledgements

The authors declare that the research was conducted in the absence of any commercial or
Immunoprofiling of polymyositis and dermatomyositis

financial relationships that could be construed as a potential conflict of interest. The present study was supported by the Young Scientists Fund of National Natural Science Foundation of China (grant No. 81601094).

Disclosure of conflict of interest

None.

Address correspondence to: Yue-Bei Luo and Huan Yang, Department of Neurology, Xiangya Hospital, Central South University, Xiangya Road, Kaifu District, Changsha 410008, China. E-mail: yuebei507@163.com (YBL); yangh69@126.com (HY)

References

Immunoprofiling of polymyositis and dermatomyositis


